RX Insider Trading
Insider Ownership Percentage: 33.65%
Insider Buying (Last 12 Months): C$43,627.95
Insider Selling (Last 12 Months): C$9,001,965.50
BioSyent Share Price & Price History
Current Price: C$10.50
Price Change: ▼ Price Decrease of -0.24 (-2.23%)
As of 04/17/2025 04:59 PM ET
BioSyent Insider Trading History
SEC Filings (Institutional Ownership Changes) for BioSyent (CVE:RX)
1.37% of BioSyent stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.
Read More on BioSyent
Today's Range
Now: C$10.50
Low: C$10.50
High: C$10.50
52 Week Range
Now: C$10.50
Volume
100 shs
Average Volume
4,537 shs
Market Capitalization
C$120.09 million
P/E Ratio
17.04
Dividend Yield
1.63%
Beta
0.93
Who are the company insiders with the largest holdings of BioSyent?
BioSyent's top insider shareholders include:
- BioSyent Inc (Insider)
- FAX Capital Corp (Insider)
- Larry Andrews (Director)
- Peter Douglas Lockhard (Director)
- Rene Goehrum (Director)
- Robert Joseph March (Senior Officer)
- Seyed Ahmad Ashrafi (Director)
- Sharan Raghubir (Senior Officer)
Learn More about top insider investors at BioSyent.